Rising Research on ICI-Associated Cardiotoxicity: 2016-2025 Bibliometric Analysis
The significant increase in research on immune checkpoint inhibitor-associated cardiotoxicity signals a critical shift in the understanding and management of these therapies. Pharma companies must stay informed to adapt their safety profiles and risk management strategies accordingly.
Phase III
Oncology / Immune Checkpoint Inhibitors
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The significant increase in research on immune checkpoint inhibitor-associated cardiotoxicity signals a critical shift in the understanding and management of these therapies. Pharma companies must stay informed to adapt their safety profiles and risk management strategies accordingly.
Why it matters
The significant increase in research on immune checkpoint inhibitor-associated cardiotoxicity signals a critical shift in the understanding and management of these therapies. Pharma companies must stay informed to adapt their safety profiles and risk management strategies accordingly.
What changed
Other
Analysis
Research output on immune checkpoint inhibitor-associated cardiotoxicity has surged from 9 publications in 2016 to 236 in 2025, indicating heightened academic focus.
The significant increase in research on immune checkpoint inhibitor-associated cardiotoxicity signals a critical shift in the understanding and management of these therapies. Pharma companies must stay informed to adapt their safety profiles and risk management strategies accordingly.
Watch for emerging studies on combination regimens and long-term cardiovascular outcomes, as well as shifts in clinical guidelines.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.